Poviztra 0.25mg FlexTouch is used to:

• Manage obesity: It is used with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.

• Manage overweight with weight-related health conditions: It may be prescribed for adults with overweight who have at least one weight-related condition.

• Support cardiovascular risk reduction: Semaglutide is indicated to reduce the risk of major adverse cardiovascular events in eligible adults with established cardiovascular disease and obesity or overweight.

Poviztra 0.25mg FlexTouch contains Semaglutide, which activates GLP-1 receptors involved in appetite and food intake regulation.

It helps increase fullness and reduce hunger and food intake. It also slows stomach emptying, which can support appetite control when used with a reduced-calorie diet and increased physical activity.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and herbal supplements you take.

• Insulin or sulfonylureas: Using Semaglutide with these medicines may increase the risk of low blood sugar.

• Other GLP-1 medicines or Semaglutide products: Do not use Poviztra with another Semaglutide-containing medicine or GLP-1 receptor agonist unless prescribed.

• Oral medicines: Semaglutide can delay stomach emptying and may affect the absorption of some medicines taken by mouth.

• Store Poviztra 0.25mg FlexTouch in a refrigerator at 2°C to 8°C.

• Do not freeze it or use it if it has been frozen.

• Keep the pen protected from light.

• Keep it out of the sight and reach of children.

• Follow the product packaging instructions for storage after first use.

Poviztra 0.25mg FlexTouch is injected once a week under the skin of the abdomen, thigh or upper arm.

The 0.25mg strength is the starting dose and is generally used for the first four weeks. It is not the usual maintenance dose. The dose is then increased gradually according to your doctor's instructions and how well you tolerate treatment.

Use the FlexTouch pen only after receiving proper instruction on the injection technique. Use a new needle for each injection and do not share the pen.

If you miss a dose, follow the missed-dose instructions supplied with your product and prescription. Do not take two doses together to make up for a missed dose.

Common side effects:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal pain

• Headache

• Dizziness

• Indigestion

• Decreased appetite

These effects may occur when treatment is started and often become less noticeable as the body adjusts.

Serious side effects:

• Severe or persistent abdominal pain

• Severe allergic reactions

• Persistent vomiting or diarrhoea causing dehydration

• Gallstones or gallbladder inflammation

• Sudden or worsening changes in vision

• Low blood sugar when used with insulin or sulfonylureas

Seek medical attention if severe or persistent symptoms occur.

• Use the 0.25mg dose only as prescribed. It is intended to start treatment rather than provide the usual maintenance dose.

• Do not increase the dose earlier than advised.

• Drink enough fluids if vomiting or diarrhoea occurs.

• Rotate injection sites regularly.

• Use a new needle for every injection.

• Never share your FlexTouch pen.

• Tell your doctor before surgery or deep sedation.

• Report severe abdominal pain or changes in vision promptly.